Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib clinical trial for treatment of Idiopathic Pulmonary Fibrosis (IPF)

Next Previous
Trial Profile

A Phase Ib clinical trial for treatment of Idiopathic Pulmonary Fibrosis (IPF)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RC 0315 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 08 Jan 2026 Status changed to recruiting.
  • 08 Jan 2026 According to Remedy Cell media release, today announces the initiation of partially-blinded randomized phase 1b single and repeat dose (4-cohort) safety & tolerability study of RC-0315/Placebo administered intra-bronchially to idiopathic pulmonary fibrosis patients.
  • 12 Mar 2025 According to Remedy Cell media release, Remedy Cell and Qureight collaborated to validate RC-0315's mechanism of action in idiopathic pulmonary fibrosis (IPF).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top